Skip to content

John Mendelson

California Pacific Medical Center

5 papers in the library · 281 citations · publishing 2000-2019

Papers

Cardiovascular Effects of 3,4-Methylenedioxymethamphetamine: A Double-Blind, Placebo-Controlled Trial

Annals of Internal Medicine December 19, 2000 Steven J. Lester, Matthew J. Baggott, Susette Welm et al. 140 citations

A modest oral dose of MDMA (1.5 mg/kg) increases heart rate by 28 beats per minute, systolic blood pressure by 25 mm Hg, diastolic blood pressure by 7 mm Hg, and cardiac output by 2 L per minute in healthy adults who have used the drug before. These cardiovascular effects are similar to those of the heart stimulant dobutamine at doses of 20 to 40 micrograms per kilogram per minute. Unlike dobutamine, MDMA shows no measurable effect on the heart's pumping strength (inotropism). The findings suggest that even moderate MDMA use raises myocardial oxygen demand without enhancing the heart's contractile force.

Use patterns and self-reported effects of Salvia divinorum: an internet-based survey.

Drug and alcohol dependence October 1, 2010 Matthew J Baggott, Earth Erowid, Fire Erowid et al. 78 citations

A survey of 500 individuals who had used Salvia divinorum found that 92.6% typically smoked or vaporized the plant, with acute effects lasting about 14 minutes on average. Most participants (80.6%) said they would use it again, and 38.4% described the experience as unique. On at least one occasion, 25.8% reported persisting positive effects lasting 24 hours or more, often an increased sense of well-being, while 4.4% reported persisting negative effects, most commonly anxiety. These findings suggest that Salvia divinorum may produce subacute improvements in mood, which is unusual for a non-medically used drug.

Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans

PLoS ONE December 2, 2010 Gantt P. Galloway, Jennifer D. Siegrist, Lynn C. Robertson et al. 22 citations

A double-blind placebo-controlled study found that the hallucinogen MDA increases closed-eye visions and mystical-type experiences. People who had more intense visions tended to perform worse on tests of contour integration and object recognition, suggesting that drug-induced hallucinations may be stronger in individuals with poorer perceptual processing. This points to possible shared mechanisms with hallucinations in psychiatric and neurological conditions.

Effects of MDMA on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting

bioRxiv (Cold Spring Harbor Laboratory) June 23, 2015 Matthew J. Baggott, Jeremy Coyle, Jennifer D. Siegrist et al. 21 citations preprint

MDMA produces a prosocial syndrome that facilitates emotional disclosure by increasing feelings of authenticity and decreasing concerns about negative evaluation by others. In a within-subjects double-blind placebo controlled study of 1.5 mg/kg oral MDMA, the drug showed both sedative- and stimulant-like effects, including increased self-report anxiety, but positively altered self-evaluation and reduced social anxiety. MDMA also increased how comfortable participants felt describing emotional memories, consistent with the suggestion that it represents a novel pharmacological class.

Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers

Journal of Psychoactive Drugs March 15, 2019 Matthew J. Baggott, Kathleen J. Garrison, Jeremy Coyle et al. 20 citations

The drug MDA, an entactogen similar to MDMA (ecstasy), produces longer-lasting emotional and physiological effects than MDMA. In a controlled experiment with healthy volunteers, a single oral dose of 1.4 mg/kg MDA increased heart rate, blood pressure, and stress hormones (cortisol and prolactin) to levels comparable to those from a 1.5 mg/kg dose of MDMA. However, participants' self-reported drug effects from MDA remained elevated for at least 8 hours, whereas MDMA effects subsided by 6 hours. Blood measurements showed that MDA and its metabolite HMA reached peak concentrations of about 229 µg/L and 92 µg/L, respectively. Because the two drugs had similar blood-level profiles, the longer duration of MDA's effects likely stems from differences in how it acts on the brain rather than from slower elimination.